Gilead Sciences, Inc. Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Gilead Sciences, Inc. is a biopharmaceutical company focused on HIV, viral hepatitis, oncology, and inflammation. The company operates as a large accelerated filer with headquarters in Foster City, California. As of April 30, 2026, there were approximately 1.24 billion shares of common stock outstanding.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $6,960 | $6,667 |
| Net Income | $2,021 | $1,315 |
| Diluted Earnings Per Share | $1.61 | $1.04 |
| Operating Cash Flow | $2,544 | $1,757 |
| Cash and Cash Equivalents | $7,628 | $7,926 |
| Total Debt (Net) | $22,174 | $24,937 |
| Product Gross Margin | 79.2% | 76.7% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 4% year-over-year, driven by a 10% increase in HIV product sales (led by Biktarvy and Descovy) and a 37% increase in Trodelvy sales. This was partially offset by a 52% decline in Veklury sales due to lower COVID-19 hospitalization rates.
- Profitability Surge: Net income rose 54% to $2.0 billion. This was primarily due to net unrealized gains from equity securities (compared to losses in 2025), higher product sales, and lower acquired in-process research and development (IPR&D) expenses ($107M vs. $253M).
- Debt Reduction: Total debt decreased by approximately $2.8 billion, largely due to the repayment of $2.75 billion in senior unsecured notes maturing in March 2026.
- Shareholder Returns: The company repurchased $419 million of common stock and declared a quarterly dividend of $0.82 per share.
Guidance, Outlook, and Risks
Outlook Update: Management expects to record approximately $11.5 billion in charges to Acquired IPR&D expenses in the second quarter of 2026 related to recent acquisitions (Arcellx, Tubulis, and Ouro Medicines). Consequently, the company anticipates a net loss for both the second quarter and the full year 2026.
Recent Acquisitions:
- Arcellx: Acquired for approximately $7.1 billion in cash plus contingent value rights to strengthen oncology portfolio (anito-cel).
- Tubulis: Agreed to acquire for ~$3.2 billion upfront plus milestones for ADC technology.
- Ouro Medicines: Agreed to acquire for ~$1.7 billion upfront plus milestones for T cell engager therapies.
Risks and Contingencies:
- Regulatory & Pricing: Significant exposure to the Inflation Reduction Act (IRA), including Medicare price negotiations (Biktarvy selected for 2028) and potential tariffs on pharmaceutical imports (100% tariffs announced for H2 2026, though exemptions may apply).
- Legal Proceedings: Ongoing antitrust litigation regarding HIV drugs (Phase II claims pending) and product liability lawsuits involving kidney/bone injuries. A settlement regarding Veklury generic entry was reached for May 2041.
- Supply Chain: Risks related to third-party manufacturers and geopolitical factors affecting raw material supply.
Investor Verification Checklist
- Q2 2026 Earnings Impact: Verify the timing and magnitude of the expected $11.5 billion IPR&D charge and its effect on the full-year 2026 net loss.
- Acquisition Integration: Monitor the closing status and regulatory approvals for Tubulis and Ouro Medicines, and the integration of Arcellx.
- IRA and Tariff Exposure: Assess the specific financial impact of the 2028 Biktarvy Medicare price negotiation and the potential application of 100% import tariffs on Gilead's supply chain.
- Legal Outcomes: Track the status of the Phase II antitrust trial (scheduled for Jan 2027) and the product liability bellwether trial (scheduled for March 2027).
- Debt Maturity Profile: Review the remaining debt schedule following the March 2026 repayment and the new $1.1 billion term loan facility entered in April 2026.